Skip to Main Content
Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 2021, Issue 1
December 10 2021
Issue Cover
In this Issue

Table of Contents

ALL: New Directions for Adult Patients

MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?
Nicola Gökbuget
View Articletitled, MRD in adult Ph/<em>BCR-ABL</em>-negative ALL: how best to eradicate?
Relapsed ALL: CAR T vs transplant vs novel therapies
Noelle V. Frey
View Articletitled, Relapsed ALL: CAR T vs transplant vs novel therapies
Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?
Marlise R. Luskin
View Articletitled, Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?

AML: So Many Options, So Little Time

What to use to treat AML: the role of emerging therapies
Felicitas Thol
View Articletitled, What to use to treat AML: the role of emerging therapies
Whom should we treat with novel agents? Specific indications for specific and challenging populations
Lindsay Wilde,Margaret Kasner
View Articletitled, Whom should we treat with novel agents? Specific indications for specific and challenging populations

Challenges in Multiple Myeloma Treatment

High-risk multiple myeloma: how to treat at diagnosis and relapse?
María-Victoria Mateos,Borja Puertas Martínez,Verónica González-Calle
View Articletitled, High-risk multiple myeloma: how to treat at diagnosis and relapse?
Minimal residual disease in multiple myeloma: why, when, where
Andrew J. Yee,Noopur Raje
View Articletitled, Minimal residual disease in multiple myeloma: why, when, where
Treatment of older adult or frail patients with multiple myeloma
Shakira J. Grant,Ciara L. Freeman,Ashley E. Rosko
View Articletitled, Treatment of older adult or frail patients with multiple myeloma

CLL: Extending Survival

Upfront therapy: the case for continuous treatment
Constantine S. Tam
View Articletitled, Upfront therapy: the case for continuous treatment
Frontline treatment in CLL: the case for time-limited treatment
Vincent Lévy,Alain Delmer,Florence Cymbalista
View Articletitled, Frontline treatment in CLL: the case for time-limited treatment
Is there a role for anti-CD20 antibodies in CLL?
Harsh R. Shah,Deborah M. Stephens
View Articletitled, Is there a role for anti-CD20 antibodies in CLL?

Clotting and Bleeding Conundrums

Unexplained arterial thrombosis: approach to diagnosis and treatment
Jori E. May,Stephan Moll
View Articletitled, Unexplained arterial thrombosis: approach to diagnosis and treatment
Cryptogenic oozers and bruisers
Kristi J. Smock,Karen A. Moser
View Articletitled, Cryptogenic oozers and bruisers
Clots in unusual places: lots of stress, limited data, critical decisions
Carol Mathew,Marc Zumberg
View Articletitled, Clots in unusual places: lots of stress, limited data, critical decisions
Evidence-Based Minireview: Should warfarin or a direct oral anticoagulant be used in patients presenting with thrombosis in the splanchnic or cerebral veins?
Carol Mathew,Marc Zumberg
View Articletitled, Evidence-Based Minireview: Should warfarin or a direct oral anticoagulant be used in patients presenting with thrombosis in the splanchnic or cerebral veins?

CML: Success Breeds More Success

TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission?
Andreas Hochhaus,Thomas Ernst
View Articletitled, TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission?
Lifelong TKI therapy: how to manage cardiovascular and other risks
Michael J. Mauro
View Articletitled, Lifelong TKI therapy: how to manage cardiovascular and other risks
Blast and accelerated phase CML: room for improvement
Joan How,Vinayak Venkataraman,Gabriela Soriano Hobbs
View Articletitled, Blast and accelerated phase CML: room for improvement

Coagulation Laboratory Potpourri

Direct oral anticoagulant (DOAC) interference in hemostasis assays
Karen A. Moser,Kristi J. Smock
View Articletitled, Direct oral anticoagulant (DOAC) interference in hemostasis assays

Dameshek's Riddle in Practice: What Do Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, and “Hypoplastic” Leukemia Have in Common?

The clinical and laboratory evaluation of patients with suspected hypocellular marrow failure
Siobán Keel,Amy Geddis
View Articletitled, The clinical and laboratory evaluation of patients with suspected hypocellular marrow failure
When does a PNH clone have clinical significance?
Daria V. Babushok
View Articletitled, When does a PNH clone have clinical significance?
When to worry about inherited bone marrow failure and myeloid malignancy predisposition syndromes in the setting of a hypocellular marrow
Anupama Narla
View Articletitled, When to worry about inherited bone marrow failure and myeloid malignancy predisposition syndromes in the setting of a hypocellular marrow

Defeating Diffuse, Double-Hit, and Dogged Non-Hodgkin Lymphoma

Double-hit lymphoma: optimizing therapy
Kieron Dunleavy
View Articletitled, Double-hit lymphoma: optimizing therapy
Relapsed disease: off-the-shelf immunotherapies vs customized engineered products
Reem Karmali
View Articletitled, Relapsed disease: off-the-shelf immunotherapies vs customized engineered products

Emerging Therapies and Considerations for Sickle Cell Disease

Gene therapy for sickle cell disease: where we are now?
Julie Kanter,Corey Falcon
View Articletitled, Gene therapy for sickle cell disease: where we are now?
Hematopoietic cell transplantation for sickle cell disease: updates and future directions
Lakshmanan Krishnamurti
View Articletitled, Hematopoietic cell transplantation for sickle cell disease: updates and future directions
Evidence-Based Minireview: In young children with severe sickle cell disease, do the benefits of HLA-identical sibling donor HCT outweigh the risks?
Niketa Shah,Lakshmanan Krishnamurti
View Articletitled, Evidence-Based Minireview: In young children with severe sickle cell disease, do the benefits of HLA-identical sibling donor HCT outweigh the risks?
Clinical trial considerations in sickle cell disease: patient-reported outcomes, data elements, and the stakeholder engagement framework
Sherif M. Badawy
View Articletitled, Clinical trial considerations in sickle cell disease: patient-reported outcomes, data elements, and the stakeholder engagement framework

Hemophilia Update: Our Cup Runneth Over

How do we optimally utilize factor concentrates in persons with hemophilia?
Ming Y. Lim
View Articletitled, How do we optimally utilize factor concentrates in persons with hemophilia?
Evidence-Based Minireview: For overweight or obese persons with hemophilia A, should factor VIII dosing be based on ideal or actual body weight?
Nicoletta Machin,Ming Y. Lim
View Articletitled, Evidence-Based Minireview: For overweight or obese persons with hemophilia A, should factor VIII dosing be based on ideal or actual body weight?
Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?
Patrick Ellsworth,Alice Ma
View Articletitled, Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?
Hemophilia gene therapy: ushering in a new treatment paradigm?
Lindsey A. George
View Articletitled, Hemophilia gene therapy: ushering in a new treatment paradigm?

Hodgkin Lymphoma: Cure and Optimal Survivorship

Controversies in the management of early-stage Hodgkin lymphoma
Kristie A. Blum
View Articletitled, Controversies in the management of early-stage Hodgkin lymphoma
How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents
Julia Driessen,Sanne H. Tonino,Alison J. Moskowitz,Marie José Kersten
View Articletitled, How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors
Narendranath Epperla,Mehdi Hamadani
View Articletitled, Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors

How Can We Ensure That Everyone Who Needs a Transplant Can Get One?

Allogeneic hematopoietic cell transplantation for older patients
Richard J. Lin,Andrew S. Artz
View Articletitled, Allogeneic hematopoietic cell transplantation for older patients
Increasing access to allogeneic hematopoietic cell transplant: an international perspective
Vanderson Rocha,Giancarlo Fatobene,Dietger Niederwieser,for the Brazilian Society of Bone Marrow Transplantation and the Worldwide Network for Blood and Marrow Transplantation
View Articletitled, Increasing access to allogeneic hematopoietic cell transplant: an international perspective
Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics
Sanghee Hong,Navneet S. Majhail
View Articletitled, Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics

Immunology 101: What the Practicing Hematologist Needs to Know

Immunology 101: fundamental immunology for the practicing hematologist
Shannon A. Carty
View Articletitled, Immunology 101: fundamental immunology for the practicing hematologist
How immunodeficiency can lead to malignancy
Sung-Yun Pai,Kathryn Lurain,Robert Yarchoan
View Articletitled, How immunodeficiency can lead to malignancy
Modified T cells as therapeutic agents
Nathan Singh
View Articletitled, Modified T cells as therapeutic agents

Indolent Lymphomas

What factors guide treatment selection in mycosis fungoides and Sezary syndrome?
Youn H. Kim
View Articletitled, What factors guide treatment selection in mycosis fungoides and Sezary syndrome?
Follicular lymphoma: is there an optimal way to define risk?
Carla Casulo
View Articletitled, Follicular lymphoma: is there an optimal way to define risk?
Does MRD have a role in the management of iNHL?
Ilaria Del Giudice,Irene Della Starza,Robin Foà
View Articletitled, Does MRD have a role in the management of iNHL?

Inherited Red Cell Disorders Beyond Hemoglobinopathies

Diagnosis and clinical management of red cell membrane disorders
Theodosia A. Kalfa
View Articletitled, Diagnosis and clinical management of red cell membrane disorders
Diagnosis and clinical management of enzymopathies
Lucio Luzzatto
View Articletitled, Diagnosis and clinical management of enzymopathies
Diamond-Blackfan anemia
Lydie M. Da Costa,Isabelle Marie,Thierry M. Leblanc
View Articletitled, Diamond-Blackfan anemia

It Takes a Village: Maximizing Supportive Care and Minimizing Toxicity During Childhood Leukemia Therapy

Fungal diagnostic testing and therapy: navigating the neutropenic period in children with high-risk leukemia
Brian T. Fisher
View Articletitled, Fungal diagnostic testing and therapy: navigating the neutropenic period in children with high-risk leukemia
Minimizing cardiac toxicity in children with acute myeloid leukemia
Hari K. Narayan,Kelly D. Getz,Kasey J. Leger
View Articletitled, Minimizing cardiac toxicity in children with acute myeloid leukemia
Managing therapy-associated neurotoxicity in children with ALL
Deepa Bhojwani,Ravi Bansal,Alan S. Wayne
View Articletitled, Managing therapy-associated neurotoxicity in children with ALL

Let the CHIP(s) Fall Where They May? Burdens and Benefits of Diagnosing Clonal Hematopoiesis

CHIP: is clonal hematopoiesis a surrogate for aging and other disease?
Lukasz P. Gondek
View Articletitled, CHIP: is clonal hematopoiesis a surrogate for aging and other disease?
Mechanisms of somatic transformation in inherited bone marrow failure syndromes
Haruna Batzorig Choijilsuren,Yeji Park,Moonjung Jung
View Articletitled, Mechanisms of somatic transformation in inherited bone marrow failure syndromes
When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)?
Afaf E. W. G. Osman
View Articletitled, When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)?

Management Strategies for Sickle Cell Disease

Optimizing management of sickle cell disease in patients undergoing surgery
Charity I. Oyedeji,Ian J. Welsby
View Articletitled, Optimizing management of sickle cell disease in patients undergoing surgery
Treatment dilemmas: strategies for priapism, chronic leg ulcer disease, and pulmonary hypertension in sickle cell disease
Roberta C.G. Azbell,Payal Chandarana Desai
View Articletitled, Treatment dilemmas: strategies for priapism, chronic leg ulcer disease, and pulmonary hypertension in sickle cell disease

MDS: Beyond a One-Size-Fits-All Approach

Have we reached a molecular era in myelodysplastic syndromes?
Maria Teresa Voso,Carmelo Gurnari
View Articletitled, Have we reached a molecular era in myelodysplastic syndromes?
Lower risk but high risk
Amy E. DeZern
View Articletitled, Lower risk but high risk
Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS?
Daniel R. Richardson,Amy E. DeZern
View Articletitled, Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS?
Oral hypomethylating agents: beyond convenience in MDS
Elizabeth A. Griffiths
View Articletitled, Oral hypomethylating agents: beyond convenience in MDS

MPN: New Directions

MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too
Anna Falanga
View Articletitled, MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too
Evidence-Based Minireview: Are DOACs an alternative to vitamin K antagonists for treatment of venous thromboembolism in patients with MPN?
Francesca Schieppati,Anna Falanga
View Articletitled, Evidence-Based Minireview: Are DOACs an alternative to vitamin K antagonists for treatment of venous thromboembolism in patients with MPN?
Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how?
James England,Vikas Gupta
View Articletitled, Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how?
Running interferon interference in treating PV/ET: meeting unmet needs
Elizabeth A. Traxler,Elizabeth O. Hexner
View Articletitled, Running interferon interference in treating PV/ET: meeting unmet needs

Multidisciplinary Hematologic Disorders: What Is the Hematologist's Role?

Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management
Adrienne M. Hammill,Katie Wusik,Raj S. Kasthuri
View Articletitled, Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management
Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond
Karlyn A. Martin,Michael J. Cuttica
View Articletitled, Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond
Rebalanced hemostasis in liver disease: a misunderstood coagulopathy
Lara N. Roberts
View Articletitled, Rebalanced hemostasis in liver disease: a misunderstood coagulopathy

Neutropenia: Doing More with Less

Diagnosis and therapeutic decision-making for the neutropenic patient
James A. Connelly,Kelly Walkovich
View Articletitled, Diagnosis and therapeutic decision-making for the neutropenic patient
Understanding neutropenia secondary to intrinsic or iatrogenic immune dysregulation
Kelly Walkovich,James A. Connelly
View Articletitled, Understanding neutropenia secondary to intrinsic or iatrogenic immune dysregulation
Impaired myelopoiesis in congenital neutropenia: insights into clonal and malignant hematopoiesis
Julia T. Warren,Daniel C. Link
View Articletitled, Impaired myelopoiesis in congenital neutropenia: insights into clonal and malignant hematopoiesis

Perioperative Consultative Hematology: Can You Clear My Patient for Surgery?

Perioperative consultative hematology: can you clear my patient for a procedure?
Allison Elaine Burnett,Bishoy Ragheb,Scott Kaatz
View Articletitled, Perioperative consultative hematology: can you clear my patient for a procedure?
How to manage bleeding disorders in aging patients needing surgery
Mouhamed Yazan Abou-Ismail,Nathan T. Connell
View Articletitled, How to manage bleeding disorders in aging patients needing surgery
Heparin-induced thrombocytopenia and cardiovascular surgery
Allyson M. Pishko,Adam Cuker
View Articletitled, Heparin-induced thrombocytopenia and cardiovascular surgery

Pregnancy in Special Populations: Challenges and Solutions

How to evaluate and treat the spectrum of TMA syndromes in pregnancy
Marie Scully
View Articletitled, How to evaluate and treat the spectrum of TMA syndromes in pregnancy
Pregnancy in special populations: challenges and solutions practical aspects of managing von Willebrand disease in pregnancy
Ozlem Turan,Rezan Abdul Kadir
View Articletitled, Pregnancy in special populations: challenges and solutions practical aspects of managing von Willebrand disease in pregnancy
Prevention and management of venous thromboembolism in pregnancy: cutting through the practice variation
Leslie Skeith
View Articletitled, Prevention and management of venous thromboembolism in pregnancy: cutting through the practice variation

Survivorship After Allogeneic Hematopoietic Cell Transplant

Psychosocial and financial issues after hematopoietic cell transplantation
David Buchbinder,Nandita Khera
View Articletitled, Psychosocial and financial issues after hematopoietic cell transplantation
Noninfectious lung complications of hematopoietic cell transplantation
Kirsten M. Williams
View Articletitled, Noninfectious lung complications of hematopoietic cell transplantation
Infectious complications and vaccines
Per Ljungman
View Articletitled, Infectious complications and vaccines

The Changing Landscape of Alpha- and Beta-Thalassemia Diagnosis and Treatment

Advances in the management of α-thalassemia major: reasons to be optimistic
Paulina Horvei,Tippi MacKenzie,Sandhya Kharbanda
View Articletitled, Advances in the management of α-thalassemia major: reasons to be optimistic
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation
Arielle L. Langer,Erica B. Esrick
View Articletitled, β-Thalassemia: evolving treatment options beyond transfusion and iron chelation
Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia
Cheryl Mensah,Sujit Sheth
View Articletitled, Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia

The Covid Crash: Lessons Learned from a World on Pause

How to recognize and manage COVID-19-associated coagulopathy
Gloria F. Gerber,Shruti Chaturvedi
View Articletitled, How to recognize and manage COVID-19-associated coagulopathy
COVID-19 and thrombosis: searching for evidence
Bright Thilagar,Mohamad Beidoun,Ruben Rhoades,Scott Kaatz
View Articletitled, COVID-19 and thrombosis: searching for evidence
Passive immune therapies: another tool against COVID-19
Lise J. Estcourt
View Articletitled, Passive immune therapies: another tool against COVID-19

Update in Graft-versus-Host Disease

Acute GVHD: think before you treat
Laura F. Newell,Shernan G. Holtan
View Articletitled, Acute GVHD: think before you treat
Updates in chronic graft-versus-host disease
Betty K. Hamilton
View Articletitled, Updates in chronic graft-versus-host disease
What else do I need to worry about when treating graft-versus-host disease?
Areej El-Jawahri
View Articletitled, What else do I need to worry about when treating graft-versus-host disease?

What's New in Plasma Cell Disorders?

Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events
Ola Landgren
View Articletitled, Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events
Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies
Alissa Visram,Joselle Cook,Rahma Warsame
View Articletitled, Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies
AL amyloidosis: untangling new therapies
Susan Bal,Heather Landau
View Articletitled, AL amyloidosis: untangling new therapies

What's New in the Transfusion Management of Sickle Cell Disease?

How to avoid the problem of erythrocyte alloimmunization in sickle cell disease
France Pirenne,Aline Floch,Anoosha Habibi
View Articletitled, How to avoid the problem of erythrocyte alloimmunization in sickle cell disease
Indications for transfusion in the management of sickle cell disease
Hyojeong Han,Lisa Hensch,Venée N. Tubman
View Articletitled, Indications for transfusion in the management of sickle cell disease
Management of hemolytic transfusion reactions
Jeanne E. Hendrickson,Ross M. Fasano
View Articletitled, Management of hemolytic transfusion reactions
All Issues
Medical consult: aHUS, TTP? How to distinguish and what to do
Management of limited-stage Hodgkin lymphoma
Consumptive coagulopathy in the ICU
Pyruvate kinase activators for treatment of pyruvate kinase deficiency
Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells
  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal